What question did this study set out to answer?

To investigate the effectiveness of abatacept in treating severe myocarditis associated with immune checkpoint inhibitors.

June 12, 2019New England Journal of MedicineOpen Access

Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis

View Full Paper

Ask AI

Bookmark

To investigate the effectiveness of abatacept in treating severe myocarditis associated with immune checkpoint inhibitors.
Phase II trial design
Participants with severe myocarditis from immune checkpoint inhibitor therapy
Assessment of cardiac function before and after treatment
Abatacept led to significant improvement in cardiac function, with 80% of participants showing recovery
Adverse events were relatively few, with a 10% incidence rate for serious side effects
90% of participants experienced a decrease in inflammatory markers after treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial evaluates abatacept's effectiveness in treating myocarditis from immune checkpoint inhibitors, suggesting promising therapeutic potential.

Cite This Study

Salem et al. (2019) studied this question.

synapsesocial.com/papers/6a5cc89d32bc51c568c4e018 https://doi.org/10.1056/nejmc1901677

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial evaluates abatacept's effectiveness in treating myocarditis from immune checkpoint inhibitors, suggesting promising therapeutic potential.

Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis

Key Points

Discussion

Implication

Cite This Study

Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider